Clinical validation of the Aarhus Side effect Assessment Questionnaire(ASAQ)

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Clinical validation of the Aarhus Side effect Assessment Questionnaire(ASAQ). / Kølbæk, Pernille; Thorgaard, Mette Viller; Grooss, Amalie Schnegelsberg et al.

In: Journal of Psychopharmacology, Vol. 36, No. 4, 04.2022, p. 507-515.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Kølbæk, P, Thorgaard, MV, Grooss, AS, Selvanathan, T, Larsen, SF, Speed, M, Dines, D & Østergaard, SD 2022, 'Clinical validation of the Aarhus Side effect Assessment Questionnaire(ASAQ)', Journal of Psychopharmacology, vol. 36, no. 4, pp. 507-515. https://doi.org/10.1177/02698811221077196

APA

CBE

MLA

Vancouver

Kølbæk P, Thorgaard MV, Grooss AS, Selvanathan T, Larsen SF, Speed M et al. Clinical validation of the Aarhus Side effect Assessment Questionnaire(ASAQ). Journal of Psychopharmacology. 2022 Apr;36(4):507-515. https://doi.org/10.1177/02698811221077196

Author

Kølbæk, Pernille ; Thorgaard, Mette Viller ; Grooss, Amalie Schnegelsberg et al. / Clinical validation of the Aarhus Side effect Assessment Questionnaire(ASAQ). In: Journal of Psychopharmacology. 2022 ; Vol. 36, No. 4. pp. 507-515.

Bibtex

@article{baf58af485d04beaa53b2b98bbe80364,
title = "Clinical validation of the Aarhus Side effect Assessment Questionnaire(ASAQ)",
abstract = "Background: Psychotropic medications are essential in the treatment of mental illness. Unfortunately, these medications are associated with side effects that may reduce adherence to treatment and quality of life. Therefore, systematic screening for side effects is fundamental to optimize treatment with psychotropic medications. Self-report of side effects is a practical alternative to time-consuming clinical assessments. We developed the Aarhus Side effect Assessment Questionnaire (ASAQ) in an attempt to strike the balance between extensive coverage of side effects and reasonable application time. Aim: The aim of the study was to validate the ASAQ using the clinician-rated Udvalg for Kliniske Undersogelser (UKU) Side Effect Scale as gold standard reference. Methods: A total of 122 inpatients and outpatients-mainly with psychotic (39%) and affective disorders (43%)-receiving treatment with psychotropic medication completed the ASAQ and the World Health Organization-Five Well-Being Index (WHO-5) and were subsequently rated on the UKU by trained raters. Results: Using the UKU as the gold standard reference, the ASAQ demonstrated sensitivity values >75% for 77% of its 30 items (ranging from 37% for cutaneous disturbances to 98% for increased sweating) and specificity values >75% for 47% of its 30 items (ranging from 28% for reduced sleep to 98% for micturition disturbances). While 17% of the participants considered discontinuing their medication, 24% had recently refrained from taking their medication as prescribed. A negative correlation was found between the ASAQ and the WHO-5 and total scores (Pearson's correlation coefficient = -0.44). Conclusions: The self-reported ASAQ seems to be a sensitive tool for detecting side effects of psychotropic medications.",
keywords = "Psychopharmacology, drug-related side effects and adverse reactions, psychiatric status rating scales, quality of life, self-report",
author = "Pernille K{\o}lb{\ae}k and Thorgaard, {Mette Viller} and Grooss, {Amalie Schnegelsberg} and Thusitha Selvanathan and Larsen, {Sofie Fly} and Maria Speed and David Dines and {\O}stergaard, {S{\o}ren Dinesen}",
year = "2022",
month = apr,
doi = "10.1177/02698811221077196",
language = "English",
volume = "36",
pages = "507--515",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = ": SAGE Publications ",
number = "4",

}

RIS

TY - JOUR

T1 - Clinical validation of the Aarhus Side effect Assessment Questionnaire(ASAQ)

AU - Kølbæk, Pernille

AU - Thorgaard, Mette Viller

AU - Grooss, Amalie Schnegelsberg

AU - Selvanathan, Thusitha

AU - Larsen, Sofie Fly

AU - Speed, Maria

AU - Dines, David

AU - Østergaard, Søren Dinesen

PY - 2022/4

Y1 - 2022/4

N2 - Background: Psychotropic medications are essential in the treatment of mental illness. Unfortunately, these medications are associated with side effects that may reduce adherence to treatment and quality of life. Therefore, systematic screening for side effects is fundamental to optimize treatment with psychotropic medications. Self-report of side effects is a practical alternative to time-consuming clinical assessments. We developed the Aarhus Side effect Assessment Questionnaire (ASAQ) in an attempt to strike the balance between extensive coverage of side effects and reasonable application time. Aim: The aim of the study was to validate the ASAQ using the clinician-rated Udvalg for Kliniske Undersogelser (UKU) Side Effect Scale as gold standard reference. Methods: A total of 122 inpatients and outpatients-mainly with psychotic (39%) and affective disorders (43%)-receiving treatment with psychotropic medication completed the ASAQ and the World Health Organization-Five Well-Being Index (WHO-5) and were subsequently rated on the UKU by trained raters. Results: Using the UKU as the gold standard reference, the ASAQ demonstrated sensitivity values >75% for 77% of its 30 items (ranging from 37% for cutaneous disturbances to 98% for increased sweating) and specificity values >75% for 47% of its 30 items (ranging from 28% for reduced sleep to 98% for micturition disturbances). While 17% of the participants considered discontinuing their medication, 24% had recently refrained from taking their medication as prescribed. A negative correlation was found between the ASAQ and the WHO-5 and total scores (Pearson's correlation coefficient = -0.44). Conclusions: The self-reported ASAQ seems to be a sensitive tool for detecting side effects of psychotropic medications.

AB - Background: Psychotropic medications are essential in the treatment of mental illness. Unfortunately, these medications are associated with side effects that may reduce adherence to treatment and quality of life. Therefore, systematic screening for side effects is fundamental to optimize treatment with psychotropic medications. Self-report of side effects is a practical alternative to time-consuming clinical assessments. We developed the Aarhus Side effect Assessment Questionnaire (ASAQ) in an attempt to strike the balance between extensive coverage of side effects and reasonable application time. Aim: The aim of the study was to validate the ASAQ using the clinician-rated Udvalg for Kliniske Undersogelser (UKU) Side Effect Scale as gold standard reference. Methods: A total of 122 inpatients and outpatients-mainly with psychotic (39%) and affective disorders (43%)-receiving treatment with psychotropic medication completed the ASAQ and the World Health Organization-Five Well-Being Index (WHO-5) and were subsequently rated on the UKU by trained raters. Results: Using the UKU as the gold standard reference, the ASAQ demonstrated sensitivity values >75% for 77% of its 30 items (ranging from 37% for cutaneous disturbances to 98% for increased sweating) and specificity values >75% for 47% of its 30 items (ranging from 28% for reduced sleep to 98% for micturition disturbances). While 17% of the participants considered discontinuing their medication, 24% had recently refrained from taking their medication as prescribed. A negative correlation was found between the ASAQ and the WHO-5 and total scores (Pearson's correlation coefficient = -0.44). Conclusions: The self-reported ASAQ seems to be a sensitive tool for detecting side effects of psychotropic medications.

KW - Psychopharmacology

KW - drug-related side effects and adverse reactions

KW - psychiatric status rating scales

KW - quality of life

KW - self-report

U2 - 10.1177/02698811221077196

DO - 10.1177/02698811221077196

M3 - Journal article

C2 - 35234056

VL - 36

SP - 507

EP - 515

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 4

ER -